Gilead Sciences and National Institute of Allergy and Infectious Diseases (NIAID) Director Anthony Fauci, MD, said today that a NIAID study of the antiviral remdesivir has produced positive data on use of the drug for treating COVID-19. “We understand that the trial has met its primary endpoint and that NIAID will provide detailed information at an upcoming briefing,” the company said in a press release. Gilead, of Foster City, California, did not release any further information. The NIAID study is a phase 3 randomized, double-blinded clinical trial comparing use of remdesivir with a placebo in 800 COVID-19 patients. The primary outcome is time to recovery.

 

Ragesoss CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0)], from Wikimedia Commons

Read more at CIDRAP…